Acticor Biotech Announces Positive Results From Its ACTIMIS PHASE Ib/IIa Study in Patients With Acute Ischemic Stroke (AIS)

Acticor Biotech announced positive results from its ACTIMIS Phase Ib/IIa clinical trial using glenzocimab as an add-on to standard of care in patients with AIS.